Late Clinical Events Associated With COVID-19 Infection — COCO-LATE  

Covid19 Clinical Trial

Official title: Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort

Status Recruiting

Clinical Trial Summary

Several publications document the occurrence of symptoms that persist or occur late. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients. Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed.

Clinical Trial Description

Several publications document the occurrence of symptoms that persist or occur late, more than 3 weeks after the first clinical manifestations of an SARS-COV2 infection. These manifestations may be related to thromboembolic or inflammatory complications, superinfections, or other mechanisms not yet well understood, including potentially related to the persistence of SARS-COV2. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients. Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed. In parallel, the prevalence of the main symptoms observed more than 3 weeks after the onset of a COVID-19 will be estimated through partnerships with existing cohort studies in the general population or in the population followed for COVID-19, still symptomatic or not at 3 weeks of infection. Longitudinal implementation of bio-libraries will allow this cohort to also constitute a bridge between clinicians and researchers. ;

Related Conditions & MeSH terms

• COVID-19
• Covid19

• NCT number: NCT04591613
• Study type: Interventional
• Source: Tourcoing Hospital
• Contact: Olivier ROBINEAU, MD PhD
• Phone: 0320694949
• Email: orobineau@ch-tourcoing.fr
• Status: Recruiting
• Phase: N/A
• Start date: December 31, 2020
• Completion date: August 2025